Investor webcast on or before July 23 will include updates on Jaguar's cancer supportive care portfolio, including participation from Jaguar scientific team, patient advocates, and leading oncology experts on cancer therapy-related diarrhea (CTD) and oral mucositis

Cancer patients with diarrhea are 40% more likely to discontinue their therapy, and up to 40% of cancer patients experience the painful side effect of oral mucositis

SAN FRANCISCO, CA / ACCESSWIRE / June 12, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it will hold an investor webcast on or before July 23, 2024 to provide results for the company's pivotal phase 3 OnTarget trial of crofelemer for prophylaxis of diarrhea in adult cancer patients with solid tumors receiving targeted therapy, with or without standard chemotherapy. The webcast, which will provide updates on Jaguar's advancing cancer supportive care portfolio, will include members of Jaguar's scientific team, patient advocates, and leading oncology experts on two of the most common and intolerable side effects of cancer therapy: CTD and oral mucositis.